Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An update of anti-viral treatment of COVID-19
Serap Şimşek Yavuz, İpek Komşuoğlu Çelikyurt
TURKISH JOURNAL OF MEDICAL SCIENCES (2021) Vol. 51, Iss. SI-1, pp. 3372-3390
Open Access | Times Cited: 78

Showing 1-25 of 78 citing articles:

Molnupiravir and Its Antiviral Activity Against COVID-19
Lili Tian, Zehan Pang, Maochen Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 104
An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants
Xiaojing Chi, Xinhui Zhang, Shengnan Pan, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 46
After the Hurricane: Anti-COVID-19 Drugs Development, Molecular Mechanisms of Action and Future Perspectives
Hazim O. Khalifa, Yousef Al Ramahi
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 739-739
Open Access | Times Cited: 12
A Broad Antiviral Strategy: Inhibitors of Human DHODH Pave the Way for Host-Targeting Antivirals against Emerging and Re-Emerging Viruses
Yucheng Zheng, Shiliang Li, Kun Song, et al.
Viruses (2022) Vol. 14, Iss. 5, pp. 928-928
Open Access | Times Cited: 37
SARS-CoV-2 and Emerging Variants: Unmasking Structure, Function, Infection, and Immune Escape Mechanisms
Jiaqi Li, Huimin Jia, Miaomiao Tian, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 31
Surface charge changes in spike RBD mutations of SARS-CoV-2 and its variant strains alter the virus evasiveness via HSPGs: A review and mechanistic hypothesis
Zhongyun Zhang, Juan Zhang, Jiqiu Wang
Frontiers in Public Health (2022) Vol. 10
Open Access | Times Cited: 31
Niclosamide as a Promising Therapeutic Player in Human Cancer and Other Diseases
Zhan Wang, Junyi Ren, Jinxiu Du, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 24, pp. 16116-16116
Open Access | Times Cited: 31
In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2
Weijuan Shang, Wenhao Dai, Cheng Yao, et al.
Antiviral Research (2022) Vol. 208, pp. 105450-105450
Open Access | Times Cited: 29
The Potential of Nanobodies for COVID-19 Diagnostics and Therapeutics
Dhaneshree Bestinee Naidoo, Anil A. Chuturgoon
Molecular Diagnosis & Therapy (2023) Vol. 27, Iss. 2, pp. 193-226
Open Access | Times Cited: 20
Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir
Paul Andrei Negru, Andrei-Flavius Radu, Cosmin Mihai Vesa, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 147, pp. 112700-112700
Open Access | Times Cited: 27
Advances and challenges in using nirmatrelvir and its derivatives against SARS-CoV-2 infection
Wujun Chen, Bing Liang, Xiaolin Wu, et al.
Journal of Pharmaceutical Analysis (2022) Vol. 13, Iss. 3, pp. 255-261
Open Access | Times Cited: 25
Mechanism of Action of Small-Molecule Agents in Ongoing Clinical Trials for SARS-CoV-2: A Review
Lei Zhao, Song Li, Wu Zhong
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 24
Repurposing of antiviral drugs for COVID-19 and impact of repurposed drugs on the nervous system
Madhura Punekar, Manas M. Kshirsagar, Chaitanya Tellapragada, et al.
Microbial Pathogenesis (2022) Vol. 168, pp. 105608-105608
Open Access | Times Cited: 21
Peptide-based inhibitors hold great promise as the broad-spectrum agents against coronavirus
Mingxing Tang, Xin Zhang, Yanhong Huang, et al.
Frontiers in Microbiology (2023) Vol. 13
Open Access | Times Cited: 11
FORMULATION DEVELOPMENT AND PHARMACOKINETIC STUDIES OF NIRMATRELVIR LOADED SOLID LIPID NANOPARTICLES USING BOX-BEHNKEN DESIGN
S M, S Sangeetha
International Journal of Applied Pharmaceutics (2025), pp. 101-112
Open Access
Development of a general anti-viral therapeutic using cholestosome technology to exploit inhibition of intracellular viral production
Lawrence Mielnicki, Julie M. Hughes, Mary Irving, et al.
Biochemistry and Biophysics Reports (2025) Vol. 41, pp. 101922-101922
Closed Access
Inhibitors of Nucleotide Biosynthesis as Candidates for a Wide Spectrum of Antiviral Chemotherapy
Claudia S. Sepúlveda, Cybele C. Garcı́a, Elsa B. Damonte
Microorganisms (2022) Vol. 10, Iss. 8, pp. 1631-1631
Open Access | Times Cited: 18
Studying the characteristics of nanobody CDR regions based on sequence analysis in combination with 3D structures
Tuom Thi Tinh Truong, Viet Quoc Huynh, Nam Vo, et al.
Journal of Genetic Engineering and Biotechnology (2022) Vol. 20, Iss. 1, pp. 157-157
Open Access | Times Cited: 17
Target-Based Virtual Screening and LC/MS-Guided Isolation Procedure for Identifying Phloroglucinol-Terpenoid Inhibitors of SARS-CoV-2
Bo Hou, Yumin Zhang, Hanyi Liao, et al.
Journal of Natural Products (2022) Vol. 85, Iss. 2, pp. 327-336
Closed Access | Times Cited: 16
Endothelial inflammation and dysfunction in COVID-19
Yordan Sbirkov, Vasil Dzharov, Krassimira Todorova, et al.
VASA (2022) Vol. 51, Iss. 2, pp. 62-70
Open Access | Times Cited: 16
Systematic review and meta-analysis of randomized controlled trials of mesenchymal stromal cells to treat coronavirus disease 2019: is it too late?
Aidan M. Kirkham, Adrian Bailey, Risa Shorr, et al.
Cytotherapy (2022) Vol. 25, Iss. 3, pp. 341-352
Open Access | Times Cited: 15
Host genetic diversity and genetic variations of SARS-CoV-2 in COVID-19 pathogenesis and the effectiveness of vaccination
Mahda Delshad, Mohammad‐Javad Sanaei, Atieh Pourbagheri‐Sigaroodi, et al.
International Immunopharmacology (2022) Vol. 111, pp. 109128-109128
Open Access | Times Cited: 13
Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?
David Baker, Amy MacDougall, Angray S. Kang, et al.
Clinical & Experimental Immunology (2021) Vol. 207, Iss. 3, pp. 263-271
Open Access | Times Cited: 17
Exploring immunogenic CD8 + T-cell epitopes for peptide-based vaccine development against evolving SARS-CoV-2 variants: An immunoinformatics approach
Mohd Sultan Khan, Madhvi Shakya, Chandan Kumar Verma
VirusDisease (2024) Vol. 35, Iss. 4, pp. 553-566
Closed Access | Times Cited: 2
Review of preclinical data of PF-07304814 and its active metabolite derivatives against SARS-CoV-2 infection
Wujun Chen, Yingchun Shao, Xiaojin Peng, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top